← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Plex Pharmaceuticals, Inc.
San Diego, CA
$3,590,643
Total funding
7
Grants
Funding over time
peak $1.1M · FY2010–21$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$3,590,643 · 7
By mechanism
R43$2,278,761 · 6
R44$1,311,882 · 1
Investigators at Plex Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Advancing CAP4196 into in vivo Proof of Concept Translational Studies$662,896
R44 · FY2020 · EY
Advancing CAP4196 into in vivo Proof of Concept Translational Studies$648,986
R44 · FY2021 · EY
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats$300,000
R43 · FY2020 · AI
Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease$300,000
R43 · FY2015 · AI
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats$300,000
R43 · FY2021 · AI
Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease$300,000
R43 · FY2014 · AI
Selective and dual-acting Hsp90 and TRAP1 inhibitors$279,068
R43 · FY2010 · GM
Discovery and Development of Novel Glucose Dependent Partial Glucokinase Activato$201,930
R43 · FY2010 · DK
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts$162,399
R43 · FY2016 · EY
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts$149,295
R43 · FY2020 · EY
Re-purposing the small-molecule drug, tafamidis (CAP4349) for the non-surgical treatment of cataracts$149,295
R43 · FY2021 · EY
Small molecule activators of alpha-crystallin for non-surgical treatment of cataracts$136,774
R43 · FY2017 · EY